Partners

Collaborators

Our Partners

Vaccitech has established partnerships with leading institutions to support the development of its programs.

Vaccitech is seeking a partner to commercialize its lead program for universal influenza A and is also open to collaborating on its platform and other programs.

We have also entered into non-exclusive licensure of our T cell induction platform in oncology, and are committed to advancing the use of our platform for oncology in combination with checkpoint inhibitors.

Hover over the logos below for more information.
The University of Oxford is a collegiate research university located in Oxford, England, United Kingdom. While having no known date of foundation, there is evidence of teaching as far back as 1096, making it the oldest university in the English-speaking world and the world’s second-oldest surviving university.

Website

Oxford Genetics improves the design and development of biological therapeutics via DNA design and the optimisation of virus and protein expression systems.

Website

Oxford University Innovation is a wholly-owned subsidiary of the University of Oxford. OUI manages the University’s technology transfer and consulting activities and provide an innovation management service to clients around the world.

Website

Ludwig Cancer Research is an international community of distinguished scientists dedicated to preventing and controlling cancer. American businessman Daniel K. Ludwig began to support cancer research with the establishment of the Ludwig Institute for Cancer Research in 1971. Today, the scientific efforts endowed through his resources have grown to encompass the Ludwig Institute and the Ludwig Centers and professorships at six U.S. institutions.

Website

Ervaxx is pioneering the use of Dark Antigens™ to deliver targeted off-the-shelf cancer vaccines and other immunotherapies for treating and preventing cancer.

Website